{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:12:35Z","timestamp":1791177155796,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K08AR079587"],"award-info":[{"award-number":["K08AR079587"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA237619"],"award-info":[{"award-number":["CA237619"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114148","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T01:57:02Z","timestamp":1717120622000},"page":"114148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease"],"prefix":"10.1016","volume":"207","author":[{"given":"Maria A.","family":"Lopez-Olivo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johncy J.","family":"Kachira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xerxes","family":"Pundole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharm Ther"},{"issue":"11","key":"10.1016\/j.ejca.2024.114148_bib2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10105","key":"10.1016\/j.ejca.2024.114148_bib3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.ejca.2024.114148_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejca.2024.114148_bib6","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114148_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The World Incidence and Prevalence of Autoimmune Diseases is Increasing","volume":"3","author":"Lerner","year":"2015","journal-title":"Int J Celiac Dis"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00002281-200303000-00002","article-title":"Environmental epidemiology and risk factors for autoimmune disease","volume":"15","author":"Dooley","year":"2003","journal-title":"Curr Opin Rheuma"},{"issue":"3-4","key":"10.1016\/j.ejca.2024.114148_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.ejca.2024.114148_bib14","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2024.114148_bib15","unstructured":"Higgins J., Thomas J., Chandler J., et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). The Cochrane Collaboration 2023: Available from www.training.cochrane.org\/handbook."},{"key":"10.1016\/j.ejca.2024.114148_bib16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2024.114148_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12874-020-01129-1","article-title":"An evaluation of DistillerSR's machine learning-based prioritization tool for title\/abstract screening - impact on reviewer-relevant outcomes","volume":"20","author":"Hamel","year":"2020","journal-title":"Bmc Med Res Method"},{"key":"10.1016\/j.ejca.2024.114148_bib18","unstructured":"Wells G., Shea B., O.'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute 2008: Available at: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp; Accessed on: December 12, 2023."},{"issue":"9","key":"10.1016\/j.ejca.2024.114148_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ejca.2024.114148_bib20","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations","author":"Sch\u00fcnemann","year":"2013"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114148_bib22","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1177\/1078155220968150","article-title":"Nivolumab treatment for metastatic thymic epithelial tumors","volume":"27","author":"Ak","year":"2021","journal-title":"J Oncol Pharm Pr"},{"issue":"12","key":"10.1016\/j.ejca.2024.114148_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.21037\/atm-20-8124","article-title":"Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease","volume":"9","author":"Alexander","year":"2021","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.ejca.2024.114148_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/10781552221079356","article-title":"Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion","volume":"29","author":"Ansel","year":"2023","journal-title":"J Oncol Pharm Pr"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001865","article-title":"Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer","volume":"9","author":"Ardizzoni","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114148_bib26","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1136\/annrheumdis-2023-eular.6448","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CANRIO)","volume":"82","author":"Arreola","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ejca.2024.114148_bib27","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00432-021-03610-w","article-title":"Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience","volume":"147","author":"Bhatlapenumarthi","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.cgh.2020.06.031","article-title":"Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series","volume":"19","author":"Braga Neto","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ejca.2024.114148_bib31","doi-asserted-by":"crossref","first-page":"LMT51","DOI":"10.2217\/lmt-2021-0003","article-title":"Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data","volume":"10","author":"Calvo","year":"2021","journal-title":"Lung Cancer Manag"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hon.2787","article-title":"Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting","volume":"38","author":"Chan","year":"2020","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib33","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study","volume":"8","author":"Chanza","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2024.114148_bib34","article-title":"Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC)","volume":"37","author":"Chanza","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114148_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.016","article-title":"Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis","volume":"189","author":"Chavaz","year":"2023","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib36","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther"},{"issue":"15","key":"10.1016\/j.ejca.2024.114148_bib38","article-title":"Toxicities of single agent and combination immune checkpoint inhibitors in patients with autoimmune diseases","volume":"37","author":"Cytryn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.114148_bib39","doi-asserted-by":"crossref","first-page":"S726","DOI":"10.1016\/j.jtho.2019.08.1553","article-title":"Use of Immune Checkpoint Inhibitors in Patients with Advanced Lung Cancer and Pre-Existing Autoimmune Diseases","volume":"14","author":"Cytryn","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.114148_bib40","article-title":"Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases","volume":"69","author":"Danlos","year":"2017","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002612","article-title":"Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study","volume":"8","author":"De La Fuente","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ejca.2024.114148_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2021.04.022","article-title":"Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada","volume":"157","author":"Debieuvre","year":"2021","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong","year":"2021","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114148_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0000000000001314","article-title":"Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis","volume":"27","author":"Efuni","year":"2021","journal-title":"J Clin Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib46","article-title":"Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis","volume":"71","author":"Efuni","year":"2019","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","article-title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)","volume":"150","author":"Faehling","year":"2020","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib48","first-page":"327","article-title":"Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group","volume":"71","author":"Fountzilas","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/apt.16458","article-title":"Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis-a single-centre experience","volume":"54","author":"Fredrick","year":"2021","journal-title":"Aliment Pharm Ther"},{"issue":"10","key":"10.1016\/j.ejca.2024.114148_bib50","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib51","doi-asserted-by":"crossref","first-page":"612","DOI":"10.55563\/clinexprheumatol\/o5nvgv","article-title":"Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre","volume":"39","author":"Gonzalez-Mazon","year":"2021","journal-title":"Clin Exp Rheuma"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)32037-0","article-title":"Safety of Immune Checkpoint Inhibitors in Patients with Preexisting Inflammatory Bowel Disease and Microscopic Colitis","volume":"158","author":"Grover","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ejca.2024.114148_bib53","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1200\/JOP.19.00672","article-title":"Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis","volume":"16","author":"Grover","year":"2020","journal-title":"JCO Oncol Pr"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","article-title":"Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution","volume":"41","author":"Guaraldi","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"21","key":"10.1016\/j.ejca.2024.114148_bib55","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1002\/cam4.4239","article-title":"Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors","volume":"10","author":"Gulati","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.114148_bib56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.114148_bib57","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2022.2081","article-title":"Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy","volume":"8","author":"Han","year":"2022","journal-title":"Jama Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib58","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s10620-020-06441-w","article-title":"Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis","volume":"66","author":"Hayashi","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.ejca.2024.114148_bib59","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","article-title":"Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology","volume":"70","author":"Hoa","year":"2021","journal-title":"Cancer Immunol Immun"},{"issue":"7","key":"10.1016\/j.ejca.2024.114148_bib60","first-page":"822","article-title":"Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (Can-RIO)","volume":"46","author":"Jamal","year":"2019","journal-title":"J Rheuma"},{"issue":"15","key":"10.1016\/j.ejca.2024.114148_bib61","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"Jama Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib63","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib64","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","author":"Kartolo","year":"2018","journal-title":"Curr Oncol"},{"issue":"41","key":"10.1016\/j.ejca.2024.114148_bib65","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017348","article-title":"Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience","volume":"98","author":"Kaur","year":"2019","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ejca.2024.114148_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.10.344","article-title":"Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience","volume":"31","author":"Khan","year":"2020","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2024.114148_bib67","article-title":"Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs)","volume":"37","author":"Khozin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib68","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/imt-2020-0272","article-title":"Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis","volume":"13","author":"Kim","year":"2021","journal-title":"Immunotherapy"},{"issue":"11","key":"10.1016\/j.ejca.2024.114148_bib69","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib70","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/RHU.0000000000001199","article-title":"A Clinical Profile of Patients on Immune Checkpoint Inhibitors Referred to Rheumatology","volume":"26","author":"Kwok","year":"2020","journal-title":"J Clin Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib74","article-title":"Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)","volume":"71","author":"Laaouad","year":"2019","journal-title":"Arthritis Rheuma"},{"issue":"7","key":"10.1016\/j.ejca.2024.114148_bib75","first-page":"89","article-title":"The Effect of Sex on Patients With Pre-Existing Rheumatoid Arthritis and Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Data From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) Prospective Cohort","volume":"50","author":"Ladouceur","year":"2023","journal-title":"J Rheuma"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib76","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.21037\/apm.2019.10.03","article-title":"Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients","volume":"9","author":"Lau","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib77","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-210820","article-title":"Onset of connective tissue disease following anti-PD1\/PD-L1 cancer immunotherapy","volume":"77","author":"Le Burel","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib78","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/annonc\/mdw056","article-title":"The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma","volume":"27","author":"Lee","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib79","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaccao.2022.11.008","article-title":"Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy","volume":"4","author":"Lee","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"19","key":"10.1016\/j.ejca.2024.114148_bib80","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib81","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejca.2024.114148_bib82","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.14309\/00000434-201810001-00728","article-title":"Safety of Immune Checkpoint Inhibitors for Cancer Therapy in IBD Patients","volume":"113","author":"Llano","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejca.2024.114148_bib83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2020.07.023","article-title":"Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma","volume":"138","author":"Loriot","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114148_bib84","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdz249.021","article-title":"Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma","volume":"30","author":"Loriot","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib85","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib86","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"Bmc Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.ejca.2024.114148_bib88","doi-asserted-by":"crossref","first-page":"S1439","DOI":"10.1016\/j.annonc.2020.10.547","article-title":"Real-world experience of immunotherapy in elderly cancer patients in a UK cancer centre","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114148_bib89","article-title":"Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies","volume":"69","author":"Mitchell","year":"2017","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib90","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib91","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"15","key":"10.1016\/j.ejca.2024.114148_bib92","article-title":"A multidisciplinary toxicity team for cancer immunotherapy-related adverse events","volume":"36","author":"Naidoo","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib93","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2018.7268","article-title":"A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events","volume":"17","author":"Naidoo","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib94","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114148_bib95","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/0284186X.2021.1878387","article-title":"Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban community","volume":"60","author":"Ngo","year":"2021","journal-title":"Acta Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2024.114148_bib96","article-title":"Real-world outcomes of immune-related adverse events in 2,125 patients managed with immunotherapy: A United Kingdom multicenter series","volume":"38","author":"Olsson-Brown","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114148_bib97","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/1078155219872786","article-title":"The impact of corticosteroid use during anti-PD1 treatment","volume":"26","author":"Pan","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2024.114148_bib98","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2021.10.018","article-title":"Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study","volume":"160","author":"Panhaleux","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114148_bib99","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.annonc.2021.01.045","article-title":"Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience","volume":"32","author":"Patel","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2024.114148_bib100","article-title":"mmune related adverse effects (IRAEs) in patients with cancer who received immune checkpoint inhibitors (ICIs): A single center experience from rural Maine","volume":"38","author":"Patwari","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114148_bib101","article-title":"Effectiveness and tolerance of immune checkpoint blockade in a real-world lung cancer patient population","volume":"6","author":"Pease","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.114148_bib102","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1007\/s00432-023-04582-9","article-title":"Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases","volume":"149","author":"Pizuorno Machado","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.114148_bib103","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/ard-2022-222186","article-title":"Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study","volume":"81","author":"Placais","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejca.2024.114148_bib104","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/annrheumdis-2020-eular.5839","article-title":"Immune Checkpoint Inhibitor Therapy in Patients with Preexisting Sarcoidosis","volume":"79","author":"Pundole","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib105","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheuma"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib106","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib107","article-title":"Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)","volume":"71","author":"Roberts","year":"2019","journal-title":"Arthritis Rheuma"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030888","article-title":"Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients' Survival: Single Center Experience and Literature Review","volume":"15","author":"Romao","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib109","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.12998\/wjcc.v10.i6.1787","article-title":"Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy","volume":"10","author":"Rubin","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ejca.2024.114148_bib110","article-title":"Interleukin-6 Receptor Blockade for Management of Immune Checkpoint Inhibitor Related Adverse Events in Patients with Melanoma. Journal for Immunotherapy of Cancer","volume":"8","author":"Saberian","year":"2020"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib111","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib112","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting antinuclear antibodies","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2024.114148_bib113","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz338.110","article-title":"Safety of PD-1\/PD-L1 blockade in patients with preexisting positive antinuclear antibodies and autoimmune disease","volume":"30","author":"Sakakida","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114148_bib114","article-title":"Toxicities of Single Agent and Combination Immune Checkpoint Inhibitors in Patients with Pre-Existing Autoimmune Diseases","volume":"8","author":"Sandigursky","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114148_bib115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2019.08.014","article-title":"Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)","volume":"121","author":"Schadendorf","year":"2019","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.ejca.2024.114148_bib116","doi-asserted-by":"crossref","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/JIPO.JIPO_11_19","article-title":"Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and\/or Chronic Inflammatory Disorders","volume":"2","author":"Shah","year":"2019","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.ejca.2024.114148_bib118","article-title":"Safety of cancer patients with preexisting autoimmune diseases presenting in the emergency center following immune checkpoint blockade","volume":"6","author":"Shah","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114148_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120275","article-title":"Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases","volume":"438","author":"Snavely","year":"2022","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib120","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2017-0028","article-title":"Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK","volume":"5","author":"So","year":"2018","journal-title":"Melanoma Manag"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib121","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","article-title":"Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract","volume":"76","author":"Sternberg","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114148_bib122","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/jnci\/djac046","article-title":"Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy","volume":"114","author":"Tang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.114148_bib123","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/annrheumdis-2018-eular.5840","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Diseases: A Nationwide Multicenter Retrospective Study","volume":"77","author":"Tison","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ejca.2024.114148_bib124","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib125","article-title":"Safety of Immune Checkpoint Inhibitors for the Treatment of Melanoma, Bronchopulmonary and Urologic Neoplasms in Patients with Preexisting Autoimmune Disease","volume":"69","author":"Tison","year":"2017","journal-title":"Arthritis Rheuma"},{"issue":"8","key":"10.1016\/j.ejca.2024.114148_bib126","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/COC.0000000000000840","article-title":"Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data","volume":"44","author":"Tully","year":"2021","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib127","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/M20-3419","article-title":"Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease A Cohort Study","volume":"174","author":"van der Kooij","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2024.114148_bib128","article-title":"Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis","volume":"72","author":"Verspohl","year":"2020","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.ejca.2024.114148_bib129","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ejca.2024.114148_bib130","article-title":"Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study","author":"Wan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.114148_bib131","article-title":"Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study","author":"Wan","year":"2023","journal-title":"medRxiv"},{"issue":"33 (1","key":"10.1016\/j.ejca.2024.114148_bib132","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICI) in patients with autoimmune conditions","volume":"155","author":"Warner","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.114148_bib133","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114148_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3018","article-title":"FDA analysis of patients with baseline autoimmune diseases treated with PD-1\/PD-L1 immunotherapy agents","volume":"35","author":"Weinstock","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114148_bib135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000700","article-title":"Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma","volume":"8","author":"Weppler","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114148_bib136","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-018-0267-x","article-title":"Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma","volume":"18","author":"Yano","year":"2018","journal-title":"Bmc Endocr Disord"},{"issue":"9","key":"10.1016\/j.ejca.2024.114148_bib137","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CJI.0000000000000377","article-title":"Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases","volume":"44","author":"Yeung","year":"2021","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.ejca.2024.114148_bib138","doi-asserted-by":"crossref","first-page":"E274","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter","year":"2023","journal-title":"Lancet Rheuma"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib139","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2261264","article-title":"Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases","volume":"12","author":"Reid","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2024.114148_bib140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib141","doi-asserted-by":"crossref","first-page":"e946","DOI":"10.1634\/theoncologist.2020-0035","article-title":"Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders","volume":"25","author":"Antonuzzo","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114148_bib142","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-023-01306-x","article-title":"Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders","author":"Aoun","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"10.1016\/j.ejca.2024.114148_bib143","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cllc.2023.05.006","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer","volume":"24","author":"Aung","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2024.114148_bib144","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2145102","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis","volume":"18","author":"Cai","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.ejca.2024.114148_bib145","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ejca.2024.114148_bib146","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fmed.2020.00137","article-title":"Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders","volume":"7","author":"Coureau","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejca.2024.114148_bib147","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.2147\/CMAR.S283217","article-title":"Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease","volume":"13","author":"Dietz","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib148","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00281-016-0595-8","article-title":"Cancer immunotherapy in patients with preexisting autoimmune disorders","volume":"39","author":"Donia","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib149","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114148_bib150","first-page":"190","article-title":"Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease","volume":"32","author":"Johnson","year":"2018","journal-title":"Oncol-Ny"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib151","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib152","first-page":"218","article-title":"Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases","volume":"32","author":"Klavdianou","year":"2021","journal-title":"Mediterr J Rheuma"},{"issue":"1","key":"10.1016\/j.ejca.2024.114148_bib153","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: what have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark Res"},{"issue":"3","key":"10.1016\/j.ejca.2024.114148_bib154","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/apt.16217","article-title":"Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases","volume":"53","author":"Meserve","year":"2021","journal-title":"Aliment Pharm Ther"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib155","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.21037\/tlcr-20-635","article-title":"Exploring the immune-checkpoint inhibitors' efficacy\/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease","volume":"10","author":"Passiglia","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2024.114148_bib156","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit","year":"2020","journal-title":"J Thorac Dis"},{"issue":"8","key":"10.1016\/j.ejca.2024.114148_bib157","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.autrev.2019.06.005","article-title":"Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer","volume":"18","author":"Sebastiani","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejca.2024.114148_bib158","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211036526","article-title":"Immune Checkpoint Inhibitors in Special Populations","volume":"20","author":"Shan","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.114148_bib159","article-title":"The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114148_bib160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2217\/imt-2020-0230","article-title":"The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases","volume":"13","author":"Wu","year":"2021","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.ejca.2024.114148_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies","volume":"19","author":"Xie","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.ejca.2024.114148_bib162","first-page":"7747","article-title":"Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis","volume":"29","author":"Yamaguchi","year":"2021","journal-title":"Support Care Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:23:05Z","timestamp":1786969385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":162,"alternative-id":["S0959804924008049"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114148","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114148"}}